Combating cancer immunotherapy resistance: a nano‐medicine perspective DOI Creative Commons
Xiangyi Kong, Xintong Xie, Juan Wu

et al.

Cancer Communications, Journal Year: 2025, Volume and Issue: unknown

Published: April 10, 2025

Abstract Cancer immunotherapy offers renewed hope for treating this disease. However, cancer cells possess inherent mechanisms that enable them to circumvent each stage of the immune cycle, thereby evading anti‐cancer immunity and leading resistance. Various functionalized nanoparticles (NPs), modified with cationic lipids, pH‐sensitive compounds, or photosensitizers, exhibit unique physicochemical properties facilitate targeted delivery therapeutic agents tumor microenvironment (TME). These NPs are engineered modify activity. The crucial signal transduction pathways by which counteract resistance outlined, including enhancing antigen presentation, boosting activation infiltration tumor‐specific cells, inducing immunogenic cell death, counteracting immunosuppressive conditions in TME. Additionally, review summarizes current clinical trials involving NP‐based immunotherapy. Ultimately, it highlights potential nanotechnology advance

Language: Английский

Antitumor Research Based on Drug Delivery Carriers: Reversing the Polarization of Tumor-Associated Macrophages DOI
Xinyu Cao,

Shen Wan,

Bingyu Wu

et al.

Molecular Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 27, 2025

The development of malignant tumors is a complex process that involves the tumor microenvironment (TME). An immunosuppressive TME presents significant challenges to current cancer therapies, serving as key mechanism through which cells evade immune detection and play crucial role in progression metastasis. This impedes optimal effectiveness immunotherapeutic approaches, including cytokines, checkpoint inhibitors, vaccines. Tumor-associated macrophages (TAMs), major component tumor-infiltrating cells, exhibit dual functionalities: M1-like TAMs suppress tumorigenesis, while M2-like promote growth Consequently, various nanocarriers aimed at polarizing phenotypes distinct mechanisms has emerged promising therapeutic strategy inhibit escape enhance antitumor responses. Review covers origin types TAMs, common pathways regulating macrophage polarization, progression, strategies targeting aiming provide comprehensive understanding guidance for future research clinical applications.

Language: Английский

Citations

1
Immune cell targeting-mediated cytomimetic drug delivery system for BBB-penetrating and precise therapy of in situ glioma DOI Creative Commons
Xiu Wang,

Baoqin Song,

Mengru Wu

et al.

Materials Today Bio, Journal Year: 2025, Volume and Issue: unknown, P. 101694 - 101694

Published: March 1, 2025

Language: Английский

Citations

1
PD-L1/PD-1 checkpoint pathway regulates astrocyte morphogenesis and myelination during brain development DOI
Yanyan Wang, Mengtian Zhang, Tianyu Zhang

et al.

Molecular Psychiatry, Journal Year: 2025, Volume and Issue: unknown

Published: March 31, 2025

Language: Английский

Citations

0
Combating cancer immunotherapy resistance: a nano‐medicine perspective DOI Creative Commons
Xiangyi Kong, Xintong Xie, Juan Wu

et al.

Cancer Communications, Journal Year: 2025, Volume and Issue: unknown

Published: April 10, 2025

Abstract Cancer immunotherapy offers renewed hope for treating this disease. However, cancer cells possess inherent mechanisms that enable them to circumvent each stage of the immune cycle, thereby evading anti‐cancer immunity and leading resistance. Various functionalized nanoparticles (NPs), modified with cationic lipids, pH‐sensitive compounds, or photosensitizers, exhibit unique physicochemical properties facilitate targeted delivery therapeutic agents tumor microenvironment (TME). These NPs are engineered modify activity. The crucial signal transduction pathways by which counteract resistance outlined, including enhancing antigen presentation, boosting activation infiltration tumor‐specific cells, inducing immunogenic cell death, counteracting immunosuppressive conditions in TME. Additionally, review summarizes current clinical trials involving NP‐based immunotherapy. Ultimately, it highlights potential nanotechnology advance

Language: Английский

Citations

0